UY34720A - Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fumarato de dimetilo - Google Patents

Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fumarato de dimetilo

Info

Publication number
UY34720A
UY34720A UY34720A UY34720A UY34720A UY 34720 A UY34720 A UY 34720A UY 34720 A UY34720 A UY 34720A UY 34720 A UY34720 A UY 34720A UY 34720 A UY34720 A UY 34720A
Authority
UY
Uruguay
Prior art keywords
dimetilo
laquinimod
fumarate
treatment
combination
Prior art date
Application number
UY34720A
Other languages
English (en)
Inventor
Joel Flaxman Kaye
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY34720A publication Critical patent/UY34720A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Exchange Systems With Centralized Control (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

Método de tratamiento de un sujeto que sufre de esclerosis múltiple o que presenta un síndrome clínicamente aislado que comprende administrar al sujeto laquinimod como una terapia adyuvante o en combinación con DMF. Esta invención también provee un envase que comprende laquinimod y DMF para tratar a un sujeto afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado. Esta invención también provee laquinimod para su uso como una terapia adyuvante o en combinación con DMF en el tratamiento de un sujeto que sufre de esclerosis múltiple o que presenta un síndrome clínicamente aislado. Esta invención también provee una composición farmacéutica que comprende laquinimod y DMF para su uso en el tratamiento de un sujeto af ectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado. Esta invención provee asimismo el uso de laquinimod y DMF en la preparación de una combinación para tratar a un sujeto que sufre de esclerosis múltiple o que presenta un síndrome clínicamente aislado.
UY34720A 2012-03-27 2013-04-02 Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fumarato de dimetilo UY34720A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261616337P 2012-03-27 2012-03-27
US13/800,047 US20130259856A1 (en) 2012-03-27 2013-03-13 Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate

Publications (1)

Publication Number Publication Date
UY34720A true UY34720A (es) 2013-10-31

Family

ID=49235339

Family Applications (1)

Application Number Title Priority Date Filing Date
UY34720A UY34720A (es) 2012-03-27 2013-04-02 Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fumarato de dimetilo

Country Status (17)

Country Link
US (6) US20130259856A1 (es)
EP (1) EP2830623A4 (es)
JP (2) JP2015512406A (es)
KR (1) KR20150003765A (es)
CN (2) CN104470520A (es)
AR (1) AR090491A1 (es)
AU (2) AU2013239850A1 (es)
CA (1) CA2868259A1 (es)
EA (1) EA201491773A1 (es)
HK (1) HK1205941A1 (es)
IL (1) IL234687A0 (es)
MX (1) MX2014011616A (es)
SG (2) SG10201607976WA (es)
TW (1) TW201343164A (es)
UY (1) UY34720A (es)
WO (1) WO2013148690A1 (es)
ZA (1) ZA201407722B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
MX2014004420A (es) 2011-10-12 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod.
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
EA201491460A1 (ru) 2012-02-03 2015-01-30 Тева Фармасьютикал Индастриз Лтд. ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
WO2013123419A1 (en) 2012-02-16 2013-08-22 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
WO2014031844A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014031892A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
US9233927B2 (en) 2013-03-14 2016-01-12 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
EP3110408B1 (en) 2014-02-28 2019-01-16 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
GB2540163A (en) * 2015-07-07 2017-01-11 Univ London Queen Mary Combination therapy for treating multiple sclerosis
WO2017120355A1 (en) * 2016-01-06 2017-07-13 Teva Pharmaceutical Industries Ltd. Dihydroquinolines and uses thereof
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US20100144651A1 (en) * 2005-07-07 2010-06-10 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
JP5832716B2 (ja) 2005-10-19 2015-12-16 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶，及びその製造方法
SI2035001T1 (sl) 2006-06-12 2012-03-30 Teva Pharma Stabilni pripravki lakvinimoda
ES2599227T3 (es) * 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
LT2653873T (lt) 2007-02-08 2022-10-10 Biogen Ma Inc. Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti
US20100260755A1 (en) * 2009-04-09 2010-10-14 Medicinova, Inc. Ibudilast and immunomodulators combination
NZ617130A (en) * 2009-04-29 2015-06-26 Biogen Ma Inc Treatment of neurodegeneration and neuroinflammation
EP3028572A1 (en) * 2009-06-19 2016-06-08 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
ES2555279T3 (es) 2010-02-12 2015-12-30 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
CA2825009A1 (en) * 2011-01-25 2012-08-02 Novartis Ag Systems and methods for medical use of motion imaging and capture
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途

Also Published As

Publication number Publication date
EP2830623A1 (en) 2015-02-04
TW201343164A (zh) 2013-11-01
CA2868259A1 (en) 2013-10-03
ZA201407722B (en) 2016-06-29
AU2018200065A1 (en) 2018-02-01
JP2015512406A (ja) 2015-04-27
MX2014011616A (es) 2014-10-17
AR090491A1 (es) 2014-11-19
CN105853422A (zh) 2016-08-17
SG11201405755QA (en) 2014-10-30
EA201491773A1 (ru) 2015-02-27
AU2013239850A1 (en) 2014-11-06
WO2013148690A1 (en) 2013-10-03
IL234687A0 (en) 2014-11-30
US20130259856A1 (en) 2013-10-03
US20150119420A1 (en) 2015-04-30
HK1205941A1 (en) 2015-12-31
EP2830623A4 (en) 2015-09-02
SG10201607976WA (en) 2016-11-29
US20180050031A1 (en) 2018-02-22
US20170224675A1 (en) 2017-08-10
US20160000774A1 (en) 2016-01-07
CN104470520A (zh) 2015-03-25
US20170319570A1 (en) 2017-11-09
JP2017200927A (ja) 2017-11-09
KR20150003765A (ko) 2015-01-09

Similar Documents

Publication Publication Date Title
UY34720A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fumarato de dimetilo
IL252547A0 (en) Treatment of multiple sclerosis using laquinimod
UY34395A (es) ?Tratamiento de Esclerosis Múltiple con la Combinación de Laquinimod y Fingolimod?.
UY4167Q (es) Par de auriculares
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
UY34607A (es) Plantas resistentes al glifosato y métodos asociados.
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY4169Q (es) Altoparlante
CR20130354S (es) Banda de rodadura de neumático
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
HK1215147A1 (zh) 眼部護理裝置及方法
DK3019166T3 (da) A Pharmaceutical Combination for the Treatment of Melanoma
UY34186A (es) ?procedimiento para revestir una superficie con micelas y superficie revestida con micelas?.
UY34603A (es) Anticuerpos anti-asic-1 y usos de los mismos
HK1218254A1 (zh) 用拉喹莫德治療多發性硬化症
UY34483A (es) Polipeptido
UY34829A (es) Nueva dosificación y formulación
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
DK2976101T3 (da) Behandlingsfremgangsmåde
EP3108440A4 (en) Concepts for generating and managing plans of care
IL252424A0 (en) Treatment of multiple sclerosis with a combination of laquinimod and a statin
HK1223855A1 (zh) 拉喹莫德和氟吡汀組合物用於治療多發性硬化症
BR112015024771A2 (pt) cateter
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
DK3041506T3 (da) Behandlingsfremgangsmåde

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210528